|
1
|
Stillwell AP, Buettner PG, Siu SK, Stitz
RW, Stevenson AR and Ho YH: Predictors of postoperative mortality,
morbidity, and long-term survival after palliative resection in
patients with colorectal cancer. Dis Colon Rectum. 54:535–544.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cozzolino AM, Pedace L, Castori M, et al:
Analysis of the miR-34a locus in 62 patients with familial
cutaneous melanoma negative for CDKN2A/CDK4 screening. Fam Cancer.
11:201–208. 2012. View Article : Google Scholar
|
|
3
|
Nalls D, Tang SN, Rodova M, Srivastava RK
and Shankar S: Targeting epigenetic regulation of miR-34a for
treatment of pancreatic cancer by inhibition of pancreatic cancer
stem cells. PLoS One. 6:e240992011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujita Y, Kojima K, Hamada N, et al:
Effects of miR-34a on cell growth and chemoresistance in prostate
cancer PC3 cells. Biochem Biophys Res Commun. 377:114–119. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winton DJ: miR-34a sets the ‘sweet spot’
for notch in colorectal cancer stem cells. Cell Stem Cell.
12:499–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gallardo E, Navarro A, Vinolas N, et al:
miR-34a as a prognostic marker of relapse in surgically resected
non-small-cell lung cancer. Carcinogenesis. 30:1903–1909. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cole KA, Attiyeh EF, Mosse YP, et al: A
functional screen identifies miR-34a as a candidate neuroblastoma
tumor suppressor gene. Mol Cancer Res. 6:735–742. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dorn GN II: miR-34a and the cardiomyopathy
of senescence: SALT PNUTS, SALT PNUTS! Cell Metab. 17:629–630.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito T, Yagi S and Yamakuchi M:
MicroRNA-34a regulation of endothelial senescence. Biochem Biophys
Res Commun. 398:735–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghawanmeh T, Thunberg U, Castro J, Murray
F and Laytragoon-Lewin N: miR-34a expression, cell cycle arrest and
cell death of malignant mesothelioma cells upon treatment with
radiation, docetaxel or combination treatment. Oncology.
81:330–335. 2011. View Article : Google Scholar
|
|
11
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guarente L: Franklin H. Epstein Lecture:
sirtuins, aging, and medicine. N Engl J Med. 364:2235–2244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X and Kazgan N: Mammalian sirtuins and
energy metabolism. Int J Biol Sci. 7:575–587. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li YG, Zhu W, Tao JP, et al: Resveratrol
protects cardiomyocytes from oxidative stress through SIRT1 and
mitochondrial biogenesis signaling pathways. Biochem Biophys Res
Commun. 438:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui Y, Wang H, Chen H, et al: Genetic
analysis of the SIRT1 gene promoter in myocardial infarction.
Biochem Biophys Res Commun. 426:232–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Csiszar A, Labinskyy N, Jimenez R, et al:
Anti-oxidative and anti-inflammatory vasoprotective effects of
caloric restriction in aging: role of circulating factors and
SIRT1. Mech Ageing Dev. 130:518–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Olivier M, Petitjean A, Marcel V, et al:
Recent advances in p53 research: an interdisciplinary perspective.
Cancer Gene Ther. 16:1–12. 2009. View Article : Google Scholar
|
|
18
|
Lefort K, Brooks Y, Ostano P, et al: A
miR-34a-SIRT6 axis in the squamous cell differentiation network.
EMBO J. 32:2248–2263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang B, Li D and Kovalchuk O: p53 Ser15
phosphorylation and histone modifications contribute to IR-induced
miR-34a transcription in mammary epithelial cells. Cell Cycle.
12:2073–2083. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Yan J and Chen T: Expression level
of miR-34a rather than P53 gene status correlates with mutability
in related human lymphoblast cell lines. Mol Carcinog. 51:674–677.
2012. View
Article : Google Scholar
|
|
21
|
Yamakuchi M and Lowenstein CJ: MiR-34,
SIRT1 and p53: the feedback loop. Cell Cycle. 8:712–715. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Castro RE, Ferreira DM, Afonso MB, et al:
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat
liver and activated by disease severity in human non-alcoholic
fatty liver disease. J Hepatol. 58:119–125. 2013. View Article : Google Scholar
|
|
23
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kouchi Z, Fujiwara Y, Yamaguchi H,
Nakamura Y and Fukami K: Phosphatidylinositol 5-phosphate 4-kinase
type II beta is required for vitamin D receptor-dependent
E-cadherin expression in SW480 cells. Biochem Biophys Res Commun.
408:523–529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gregory RI, Chendrimada TP and Shiekhattar
R: MicroRNA biogenesis: isolation and characterization of the
microprocessor complex. Methods Mol Biol. 342:33–47.
2006.PubMed/NCBI
|
|
26
|
Krutovskikh VA and Herceg Z: Oncogenic
microRNAs (OncomiRs) as a new class of cancer biomarkers.
Bioessays. 32:894–904. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei Y, Nazari-Jahantigh M, Neth P, Weber C
and Schober A: MicroRNA-126, -145, and -155: a therapeutic triad in
atherosclerosis? Arterioscler Thromb Vasc Biol. 33:449–454. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krichevsky AM and Gabriely G: miR-21: a
small multi-faceted RNA. J Cell Mol Med. 13:39–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He L, He X, Lim LP, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dufour A, Palermo G, Zellmeier E, et al:
Inactivation of TP53 correlates with disease progression and low
miR-34a expression in previously treated chronic lymphocytic
leukemia patients. Blood. 121:3650–3657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duan W, Xu Y, Dong Y, Cao L, Tong J and
Zhou X: Ectopic expression of miR-34a enhances radiosensitivity of
non-small cell lung cancer cells, partly by suppressing the LyGDI
signaling pathway. J Radiat Res. 54:611–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feinberg-Gorenshtein G, Avigad S, Jeison
M, et al: Reduced levels of miR-34a in neuroblastoma are not caused
by mutations in the TP53 binding site. Genes Chromosomes Cancer.
48:539–543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu C, Kelnar K, Liu B, et al: The
microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pritchard DM, Watson AJ, Potten CS,
Jackman AL and Hickman JA: Inhibition by uridine but not thymidine
of p53-dependent intestinal apoptosis initiated by 5-fluorouracil:
evidence for the involvement of RNA perturbation. Proc Natl Acad
Sci USA. 94:1795–1799. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roos WP and Kaina B: DNA damage-induced
cell death: from specific DNA lesions to the DNA damage response
and apoptosis. Cancer Lett. 332:237–248. 2013. View Article : Google Scholar
|
|
36
|
Wiman KG: Strategies for therapeutic
targeting of the p53 pathway in cancer. Cell Death Differ.
13:921–926. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar
|
|
38
|
Audrito V, Vaisitti T, Rossi D, et al:
Nicotinamide blocks proliferation and induces apoptosis of chronic
lymphocytic leukemia cells through activation of the
p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res.
71:4473–4483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan J, Fan L, Mao JJ, et al: Restoration
of miR-34a in p53 deficient cells unexpectedly promotes the cell
survival by increasing NFκB activity. J Cell Biochem.
113:2903–2908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Olmos Y, Sanchez-Gomez FJ, Wild B, et al:
SirT1 regulation of antioxidant genes is dependent on the formation
of a FoxO3a/PGC-1α complex. Antioxid Redox Signal. 19:1507–1521.
2013. View Article : Google Scholar : PubMed/NCBI
|
